The following is a summary of “Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration,” published in the March 2025 issue of British Journal ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth ...

Kodiak Sciences Inc. , today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "In September of 2024 we hosted an Investor R&D Day ...

Furthermore, higher intraocular levels of IL-6 correlated with poorer BCVA outcomes over time in wet AMD patients treated with anti-VEGF monotherapy, which suggests that IL-6 inhibition in ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

Surrozen said despite SZN-043 demonstrating changes in liver function assays, there was not enough clinical benefit for ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Blindness or vision loss is a growing concern among older adults, and one of the leading causes is a condition known as ...

On Slide 17, we have laid out the competitive landscape related to dosing flexibility in the wet AMD market. The initially approved anti-VEGF drugs to treat wet AMD work well, but have lower ...

Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors for GLP-1, GIP and glucagon from United Biotechnology Co. Ltd. China-based ...